Influence of Oxidative Stress, Skeletal Muscle Mass and Obesity on Type 2 Diabetes Mellitus among Patients in Kumasi Metropolis

2014 ◽  
Vol 9 (2) ◽  
pp. 107-115
Author(s):  
Robert A. Ngala ◽  
Albert Adu Asare
2014 ◽  
Vol 61 (3) ◽  
pp. 281-287 ◽  
Author(s):  
Kanako Shishikura ◽  
Keiji Tanimoto ◽  
Satoshi Sakai ◽  
Yoshimi Tanimoto ◽  
Jungo Terasaki ◽  
...  

2019 ◽  
Vol 10 ◽  
pp. 204201881984297
Author(s):  
Hitomi Miyake ◽  
Ippei Kanazawa ◽  
Ken-ichiro Tanaka ◽  
Toshitsugu Sugimoto

Background: Patients with type 2 diabetes mellitus (T2DM) have an increased risk of muscle mass reduction. However, the association between muscle mass and mortality in T2DM remains unknown. Methods: This was a historical cohort study with the endpoint of all-cause mortality. This study included 163 Japanese men and 141 postmenopausal women with T2DM whose body compositions were evaluated using dual-energy X-ray absorptiometry. Low muscle mass was defined as a skeletal muscle mass index (SMI) of <7.0 kg/m2 for men and <5.4 kg/m2 for women. Results: During the 6-year follow-up period, 32 men and 14 women died. In a Cox regression analysis adjusted for age, T2DM duration, glycated hemoglobin, serum creatinine, fasting C-peptide, body mass index, and lean body mass were associated with the risk of mortality in men [hazard ratio (HR) = 1.81, 95% confidence interval (CI) = 1.00–3.28 per standard deviation (SD) decrease, p = 0.049] and women (HR = 4.53, 95% CI = 1.14–17.96 per SD decrease, p = 0.032). Neither fat mass nor bone mineral content was associated with mortality. Low SMI was associated with increased mortality in women (HR = 5.97, 95% CI = 1.04–34.37, p = 0.045), while the association between low SMI and mortality was marginal in men (HR = 2.38, 95% CI = 0.92–6.14, p = 0.074). Conclusions: Low muscle mass was independently associated with all-cause mortality in patients with T2DM. The preservation of skeletal muscle mass is important to protect patients with T2DM from increased mortality risk.


2020 ◽  
Vol 2020 ◽  
pp. 1-6 ◽  
Author(s):  
Chen-Ning Wu ◽  
Kai-Jen Tien

Sarcopenia is a geriatric syndrome characterized by decline of skeletal muscle mass and function. Contributing factors include nutritional, genetic, inflammatory, and endocrinal factors. The reported prevalence of sarcopenia in type 2 diabetes mellitus is high, especially in patients with poor glycemic control. Additionally, antidiabetic agents may alter the balance between protein synthesis and degradation through various mechanisms of skeletal muscle mass regulation. This study reviewed the literature on the pathogenesis of sarcopenia in diabetes mellitus and the current understanding of whether antidiabetic agents contribute positively or negatively to sarcopenia and muscle wasting.


2020 ◽  
Vol 2020 ◽  
pp. 1-7
Author(s):  
Liming Hou ◽  
Yan Liu ◽  
Xing Li ◽  
Cong Huo ◽  
Xin Jia ◽  
...  

Objective. The accelerate loss of skeletal muscle mass, strength, and function, named sarcopenia, is a progressive and generalised skeletal muscle disorder, and it is always associated with increased outcomes including falls, frailty, and disability. Diabetes mellitus is associated with significant muscle and physical complications. We aimed at clarifying the changes and risk factors of skeletal muscle mass and strength in elderly with type 2 diabetes. Methods. The study consisted of patients with type 2 diabetes ( n = 120 ) and an older general population ( n = 126 ). The skeletal muscle mass and muscle strength, as well as the serum levels of chronic inflammation, oxidative stress, homocysteine, and insulin-like factor-1 were assessed, and the correlation and regression analysis were conducted to evaluate outcomes. Results. T2DM patients exhibited lower muscle strength compared with the non-T2DM subjects ( P < 0.01 ). Among T2DM patients, serum IGF-1 levels were positively correlated with muscle strength ( r = 0.255 , P < 0.01 ) and muscle mass ( r = 0.209 , P < 0.05 ), levels of 8-OHdG were inversely correlated with muscle strength ( r = − 0.252 , P < 0.01 ), and there was a negative association between HCY and muscle mass ( r = − 0.185 , P < 0.05 ). Muscle mass and strength of patients with higher education level were significantly higher than those with lower education level ( P < 0.05 ), in male patients, muscle mass and muscle strength were significantly lower in smokers ( P < 0.01 ), and muscle mass was lower in chronic drinkers ( P < 0.05 ). Conclusions. These findings suggest that diabetic patients may be more susceptible to sarcopenia at an older age. And it also provides evidences that among elderly with diabetes mellitus, oxidative damage and HCY as well as IGF-1 are important predictors of age-dependent sarcopenia.


2008 ◽  
Vol 29 (1) ◽  
pp. 20-30 ◽  
Author(s):  
Sung Soo Chung ◽  
Min Kim ◽  
Byoung-Soo Youn ◽  
Nam Seok Lee ◽  
Ji Woo Park ◽  
...  

ABSTRACT Oxidative stress plays an important role in the pathogenesis of insulin resistance and type 2 diabetes mellitus and in diabetic vascular complications. Thiazolidinediones (TZDs), a class of peroxisome proliferator-activated receptor γ (PPARγ) agonists, improve insulin sensitivity and are currently used for the treatment of type 2 diabetes mellitus. Here, we show that TZD prevents oxidative stress-induced insulin resistance in human skeletal muscle cells, as indicated by the increase in insulin-stimulated glucose uptake and insulin signaling. Importantly, TZD-mediated activation of PPARγ induces gene expression of glutathione peroxidase 3 (GPx3), which reduces extracellular H2O2 levels causing insulin resistance in skeletal muscle cells. Inhibition of GPx3 expression prevents the antioxidant effects of TZDs on insulin action in oxidative stress-induced insulin-resistant cells, suggesting that GPx3 is required for the regulation of PPARγ-mediated antioxidant effects. Furthermore, reduced plasma GPx3 levels were found in patients with type 2 diabetes mellitus and in db/db/DIO mice. Collectively, these results suggest that the antioxidant effect of PPARγ is exclusively mediated by GPx3 and further imply that GPx3 may be a therapeutic target for insulin resistance and diabetes mellitus.


2018 ◽  
Author(s):  
Se-Hwa Kim ◽  
Soo-Kyung Kim ◽  
Young-Ju Choi ◽  
Seok-Won Park ◽  
Eun-Jig Lee ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document